Your browser is no longer supported. Please, upgrade your browser.
GLYC GlycoMimetics, Inc. daily Stock Chart
GLYC [NASD]
GlycoMimetics, Inc.
Index- P/E- EPS (ttm)-1.19 Insider Own0.80% Shs Outstand43.58M Perf Week-7.52%
Market Cap125.85M Forward P/E- EPS next Y-1.64 Insider Trans5.96% Shs Float42.61M Perf Month-2.75%
Income-51.50M PEG- EPS next Q-0.38 Inst Own93.50% Short Float6.55% Perf Quarter-21.82%
Sales9.00M P/S13.98 EPS this Y-13.80% Inst Trans-3.94% Short Ratio8.60 Perf Half Y-48.96%
Book/sh3.41 P/B0.83 EPS next Y-15.50% ROA-29.30% Target Price- Perf Year-75.98%
Cash/sh3.48 P/C0.81 EPS next 5Y- ROE-31.80% 52W Range1.82 - 13.44 Perf YTD-46.50%
Dividend- P/FCF- EPS past 5Y-17.30% ROI- 52W High-78.94% Beta2.53
Dividend %- Quick Ratio14.80 Sales past 5Y- Gross Margin- 52W Low55.49% ATR0.25
Employees57 Current Ratio14.80 Sales Q/Q- Oper. Margin- RSI (14)49.40 Volatility8.12% 8.71%
OptionableYes Debt/Eq0.00 EPS Q/Q46.10% Profit Margin- Rel Volume1.01 Prev Close2.95
ShortableYes LT Debt/Eq0.00 EarningsMay 01 BMO Payout- Avg Volume324.68K Price2.83
Recom2.20 SMA20-3.70% SMA508.80% SMA200-31.11% Volume328,281 Change-4.07%
Nov-14-19Initiated ROTH Capital Buy $12
Aug-05-19Downgrade SunTrust Buy → Hold $23 → $5
Aug-05-19Downgrade Piper Jaffray Overweight → Neutral $20 → $6
Aug-05-19Downgrade Jefferies Buy → Hold
Apr-12-19Initiated Piper Jaffray Overweight $20
Dec-18-18Initiated H.C. Wainwright Buy $24
Jul-26-16Initiated SunTrust Buy
Mar-17-15Reiterated Stifel Buy $13 → $14
May-29-20 09:00AM  GlycoMimetics to Present at Upcoming Jefferies Virtual Healthcare Conference Business Wire
May-15-20 12:30PM  GlycoMimetics to Present New Preclinical Data Highlighting Biomarkers and Potential Expanded Pipeline Opportunities at Virtual AACR Annual Meeting 2020 Business Wire +7.61%
May-12-20 03:48AM  Edited Transcript of GLYC earnings conference call or presentation 1-May-20 12:30pm GMT Thomson Reuters StreetEvents -6.39%
May-08-20 08:30AM  GlycoMimetics Announces Change to Virtual Meeting Format for 2020 Annual Meeting of Shareholders Business Wire +6.81%
May-05-20 07:18AM  Imagine Owning GlycoMimetics (NASDAQ:GLYC) And Trying To Stomach The 77% Share Price Drop Simply Wall St. -5.42%
May-01-20 09:01PM  GlycoMimetics Inc (GLYC) Q1 2020 Earnings Call Transcript Motley Fool
07:00AM  GlycoMimetics Reports Operational Highlights and Financial Results for First Quarter 2020 Business Wire
Apr-30-20 09:00AM  Compelling Data on Mechanism of Action for GlycoMimetics Late-stage Clinical Candidate Uproleselan Published in Nature Communications Business Wire
Apr-24-20 09:00AM  GlycoMimetics to Report First Quarter Financial Results on May 1, 2020 Business Wire
Apr-07-20 09:15AM  GlycoMimetics Appoints Dr. Myra Rosario Herrle as Vice President, Regulatory Affairs Business Wire
Apr-06-20 04:15PM  GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Mar-26-20 01:51AM  Edited Transcript of GLYC earnings conference call or presentation 28-Feb-20 1:30pm GMT Thomson Reuters StreetEvents
Mar-11-20 07:36AM  Daniel Junius Is The Independent Director of GlycoMimetics, Inc. (NASDAQ:GLYC) And They Just Spent US$68k On Shares Simply Wall St. -5.16%
Feb-28-20 08:07AM  GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2019 Business Wire
Feb-25-20 09:00AM  GlycoMimetics to Present at the Cowen and Company 40th Annual Health Care Conference 2020 Business Wire -5.04%
Feb-11-20 07:23AM  The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga
Feb-06-20 10:40AM  Wall Street Pros: These 3 Stocks Can Double Next Year TipRanks
Feb-04-20 09:53AM  GlycoMimetics Advances GMI-1359 Program With Patent Issuance and FDA Designations Business Wire
Jan-30-20 09:00AM  First Patient With Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics' GMI-1359 Business Wire
Jan-06-20 05:14PM  Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug. American City Business Journals
03:02PM  Md. biotech outlines path for blood cancer drug, including in China American City Business Journals
09:00AM  GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China Business Wire
Dec-19-19 11:09AM  Hedge Funds Dropped The Ball On GlycoMimetics, Inc. (GLYC) Insider Monkey
Nov-29-19 09:41AM  GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019 Business Wire
Nov-15-19 08:29PM  Edited Transcript of GLYC earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-13-19 09:00AM  GlycoMimetics to Present at Two Upcoming Investor Conferences Business Wire +5.03%
Nov-08-19 08:00AM  Pharma Sector Tops in October: Best ETFs & Stocks Zacks
Nov-07-19 08:24AM  GlycoMimetics Reports Third Quarter 2019 Financial Results and Recent Operational Developments Business Wire +6.05%
Nov-06-19 10:03AM  GlycoMimetics to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at 61st ASH Meeting Business Wire
Oct-31-19 04:15PM  GlycoMimetics to Report Third Quarter 2019 Financial Results on November 7, 2019 Business Wire -5.21%
Oct-30-19 05:23PM  GlycoMimetics, Inc. (GLYC) Is Burning These Hedge Funds Insider Monkey +7.74%
Sep-19-19 01:08PM  GlycoMimetics, Inc.'s (NASDAQ:GLYC) Single Biggest Risk For Investors Simply Wall St.
Aug-27-19 01:59AM  Edited Transcript of GLYC earnings conference call or presentation 1-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-18-19 06:25PM  Analysts Recommend These 2 Falling Knives GuruFocus.com
Aug-08-19 09:00AM  Are Options Traders Betting on a Big Move in GlycoMimetics (GLYC) Stock? Zacks
Aug-05-19 12:21PM  A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019 Benzinga -69.33%
08:56AM  GlycoMimetics stock down 53% after Phase 3 trial failure MarketWatch
06:34AM  GlycoMimetics Plummets After Phase 3 Trial of Sickle Cell Treatment Fails TheStreet.com
Aug-02-19 08:43PM  GlycoMimetics Reports Top-line Results From Pfizers Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease Business Wire
07:24AM  GlycoMimetics (GLYC) Q2 2019 Earnings Call Transcript Motley Fool
Jul-25-19 09:00AM  GlycoMimetics to Report Second Quarter 2019 Financial Results on August 1, 2019 Business Wire
Jul-23-19 10:23AM  GlycoMimetics Enters Oversold Territory Zacks
May-29-19 04:00PM  GlycoMimetics to Present at Jefferies 2019 Healthcare Conference Business Wire
May-20-19 05:15PM  Edited Transcript of GLYC earnings conference call or presentation 2-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-11-19 01:27PM  Heres What Hedge Funds Think About GlycoMimetics, Inc. (GLYC) Insider Monkey
May-06-19 09:00AM  GlycoMimetics, Inc. Announces Enrollment Completed for Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease Business Wire +5.21%
May-04-19 04:23PM  GlycoMimetics (GLYC) Q1 2019 Earnings Call Transcript Motley Fool
May-02-19 08:27AM  GlycoMimetics: 1Q Earnings Snapshot Associated Press
07:00AM  GlycoMimetics Reports First Quarter 2019 Results and Recent Operational Highlights Business Wire
06:30AM  GlycoMimetics, Inc. to Host Earnings Call ACCESSWIRE
Apr-29-19 04:00PM  GlycoMimetics Bolsters Executive Team with Appointment of Dr. Eric Feldman as Vice President, Clinical Development, and Christian Dinneen-Long as Vice President, Corporate Counsel Business Wire
Apr-25-19 04:00PM  GlycoMimetics to Report First Quarter 2019 Financial Results on May 2, 2019 Business Wire
Apr-23-19 09:15AM  GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML Business Wire
Apr-22-19 09:00AM  GlycoMimetics Announces Publication of Nature Cell Biology Paper Supporting Recently Announced Clinical Trial of GMI-1359 Business Wire
Apr-21-19 01:37AM  Edited Transcript of GLYC earnings conference call or presentation 6-Mar-19 1:30pm GMT Thomson Reuters StreetEvents
Apr-12-19 09:00AM  GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359 Business Wire
Apr-04-19 04:00PM  GlycoMimetics to Present at Upcoming Investor Conferences Business Wire
Mar-07-19 05:30PM  GlycoMimetics to Present at the Cowen and Company 39th Annual Health Care Conference 2019 Business Wire
Mar-06-19 02:46PM  Did GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Sell Shares? Simply Wall St.
12:56PM  GlycoMimetics Inc (GLYC) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:30AM  GlycoMimetics Reports Fourth Quarter and Year-End 2018 Results Business Wire
06:30AM  GlycoMimetics, Inc. to Host Earnings Call ACCESSWIRE
Mar-05-19 04:30PM  GlycoMimetics Announces Transition Plan for Board of Directors Business Wire
Feb-27-19 04:30PM  GlycoMimetics to Report Fourth Quarter and Year-End 2018 Financial Results on March 6, 2019 Business Wire
Feb-11-19 08:15AM  Detailed Research: Economic Perspectives on Waddell & Reed Financial, Kennametal, Automatic Data Processing, Trustmark, Eagle Bulk Shipping, and GlycoMimetics What Drives Growth in Today's Competitive Landscape GlobeNewswire
Dec-12-18 10:46AM  Heres What We Think About GlycoMimetics, Inc.s (NASDAQ:GLYC) CEO Pay Simply Wall St.
Dec-04-18 07:00AM  GlycoMimetics Posters at 60th ASH Annual Meeting Highlight Preclinical Data on Two New Proprietary Drug Candidates Business Wire -5.55%
Dec-03-18 07:00AM  GlycoMimetics Presents New AML Data with Uproleselan at 60th ASH Annual Meeting Business Wire
Nov-29-18 09:15AM  GlycoMimetics to Host 2018 Investor/Analyst Meeting at 60th ASH Annual Meeting on December 3, 2018 Business Wire -5.61%
Nov-28-18 09:00AM  Scott Jackson, Veteran Biopharmaceutical Executive, Joins GlycoMimetics Board of Directors Business Wire +5.21%
Nov-27-18 07:15AM  3 Top Biotech Stocks to Buy Right Now Motley Fool -8.93%
Nov-19-18 09:00AM  GlycoMimetics Enrolls First Patient in Global Phase 3 Clinical Trial of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia Business Wire
Nov-16-18 03:27AM  Edited Transcript of GLYC earnings conference call or presentation 2-Nov-18 12:30pm GMT Thomson Reuters StreetEvents
Nov-06-18 07:40AM  Report: Developing Opportunities within Stryker, Anavex Life Sciences, Engility, Baker Hughes, a GE company, GlycoMimetics, and HCP Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-02-18 07:39AM  GlycoMimetics: 3Q Earnings Snapshot Associated Press
07:30AM  GlycoMimetics Reports Third Quarter 2018 Results and Highlights Recent Company Achievements Business Wire
Nov-01-18 09:58AM  GlycoMimetics to Present Analyses from Phase 1/2 AML Trial of Uproleselan at 60th ASH Meeting Business Wire
Oct-26-18 09:00AM  GlycoMimetics to Report Third Quarter 2018 Financial Results on November 2, 2018 Business Wire
Oct-24-18 09:00AM  GlycoMimetics to Present at Upcoming Investor Conferences Business Wire -13.47%
Oct-10-18 04:54PM  Neurocrine Inks Deal with Private Biotech to Make CNS Drugs Zacks
Aug-31-18 07:45AM  Research Report Identifies FS Investment, Rush Enterprises, GlycoMimetics, Federal Signal, ATN International, and Novavax with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-29-18 04:00AM  Edited Transcript of GLYC earnings conference call or presentation 10-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-14-18 09:00AM  GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271) Business Wire
Aug-10-18 10:15PM  GlycoMimetics (GLYC) Q2 2018 Earnings Conference Call Transcript Motley Fool
03:17PM  GlycoMimetics Stock Has Substantial Upside InvestorPlace
06:30AM  GlycoMimetics, Inc. to Host Earnings Call ACCESSWIRE
Aug-09-18 04:49PM  GlycoMimetics: 2Q Earnings Snapshot Associated Press
04:05PM  GlycoMimetics Reports Second Quarter 2018 Results and Highlights Recent Company Achievements Business Wire
Aug-02-18 09:00AM  GlycoMimetics to Report Second Quarter 2018 Financial Results on August 9, 2018 Business Wire
Jul-27-18 07:50AM  Factors of Influence in 2018, Key Indicators and Opportunity within Minerals Technologies, USG, Continental Resources, Take-Two Interactive Software, Trimble, and GlycoMimetics New Research Emphasizes Economic Growth GlobeNewswire
Jul-18-18 07:20AM  Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks ACCESSWIRE
Jun-14-18 07:05AM  Free Technical Reports on Gilead Sciences and Three Additional Biotech Equities ACCESSWIRE -6.06%
Jun-01-18 04:15PM  GlycoMimetics to Present at Jefferies 2018 Global Healthcare Conference Business Wire
May-30-18 09:15AM  GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Business Wire
May-22-18 08:15AM  New Research Coverage Highlights Apollo Commercial Real Estate Finance, Drive Shack, GlycoMimetics, Dycom Industries, Apple Hospitality REIT, and Howard Hughes Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
May-03-18 04:05PM  Edited Transcript of GLYC earnings conference call or presentation 3-May-18 12:30pm GMT Thomson Reuters StreetEvents -6.49%
08:46AM  GlycoMimetics: 1Q Earnings Snapshot Associated Press
07:00AM  GlycoMimetics Reports First Quarter 2018 Results Business Wire
Apr-26-18 09:00AM  GlycoMimetics to Report First Quarter 2018 Financial Results on May 3, 2018 Business Wire
Mar-29-18 08:20AM  New Research Coverage Highlights Healthcare Trust of America, Drive Shack, Chemed, AMERISAFE, Medical Properties Trust, and GlycoMimetics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc. It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. Further, it is developing various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JUNIUS DANIEL MDirectorMar 09Buy3.4020,00068,00038,000Mar 10 06:12 PM
Magnani John L.SVP of Research, CSOJan 06Option Exercise1.12106,983119,821289,760Jan 06 06:23 PM
Magnani John L.SVP of Research, CSODec 20Option Exercise1.12106,984119,822182,777Dec 23 04:13 PM
BVF PARTNERS L P/IL10% OwnerSep 05Buy3.181,668,7465,309,9503,639,935Sep 09 04:49 PM
JUNIUS DANIEL MDirectorAug 13Buy3.1810,00031,80018,000Aug 15 04:03 PM
King Rachel K.President, CEOAug 06Option Exercise1.12166,759186,770307,144Aug 07 04:29 PM